Neonatal hypoxia ischaemia: mechanisms, models, and therapeutic challenges

LJ Millar, L Shi, A Hoerder-Suabedissen… - Frontiers in cellular …, 2017 - frontiersin.org
Neonatal hypoxia-ischaemia (HI) is the most common cause of death and disability in
human neonates, and is often associated with persistent motor, sensory, and cognitive …

NKCC1 chloride importer antagonists attenuate many neurological and psychiatric disorders

Y Ben-Ari - Trends in neurosciences, 2017 - cell.com
In physiological conditions, adult neurons have low intracellular Cl−[(Cl−) I] levels
underlying the γ-aminobutyric acid (GABA) ergic inhibitory drive. In contrast, neurons have …

Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome

G Deidda, M Parrini, S Naskar, IF Bozarth… - Nature medicine, 2015 - nature.com
Down syndrome (DS) is the most frequent genetic cause of intellectual disability, and altered
GABAergic transmission through Cl−-permeable GABAA receptors (GABAARs) contributes …

Chloride transporters controlling neuronal excitability

JC Pressey, M de Saint-Rome… - Physiological …, 2023 - journals.physiology.org
Synaptic inhibition plays a crucial role in regulating neuronal excitability, which is the
foundation of nervous system function. This inhibition is largely mediated by the …

Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 …

RM Pressler, GB Boylan, N Marlow, M Blennow… - The Lancet …, 2015 - thelancet.com
Background Preclinical data suggest that the loop-diuretic bumetanide might be an effective
treatment for neonatal seizures. We aimed to assess dose and feasibility of intravenous …

[HTML][HTML] CNS pharmacology of NKCC1 inhibitors

W Loescher, K Kaila - Neuropharmacology, 2022 - Elsevier
Abstract The Na–K–2Cl cotransporter NKCC1 and the neuron-specific K–Cl cotransporter
KCC2 are considered attractive CNS drug targets because altered neuronal chloride …

New GABA-targeting therapies for the treatment of seizures and epilepsy: II. Treatments in clinical development

E Perucca, HS White, M Bialer - CNS drugs, 2023 - Springer
The inhibitory neurotransmitter γ-aminobutyric acid (GABA) plays an important role in the
modulation of neuronal excitability, and a disruption of GABAergic transmission contributes …

Role of NKCC1 and KCC2 in epilepsy: from expression to function

R Liu, J Wang, S Liang, G Zhang, X Yang - Frontiers in neurology, 2020 - frontiersin.org
As a main inhibitory neurotransmitter in the central nervous system, γ-aminobutyric acid
(GABA) activates chloride-permeable GABAa receptors (GABAa Rs) and induces chloride …

Sex differences in the epilepsies and associated comorbidities: implications for use and development of pharmacotherapies

CA Christian, DS Reddy, J Maguire, PA Forcelli… - Pharmacological …, 2020 - Elsevier
The epilepsies are common neurologic disorders characterized by spontaneous recurrent
seizures. Boys, girls, men, and women of all ages are affected by epilepsy and, in many …

A pilot randomized, controlled, double‐blind trial of bumetanide to treat neonatal seizures

JS Soul, AM Bergin, C Stopp, B Hayes… - Annals of …, 2021 - Wiley Online Library
Objective In the absence of controlled trials, treatment of neonatal seizures has changed
minimally despite poor drug efficacy. We tested bumetanide added to phenobarbital to treat …